Press release
Tencent Healthcare Unveils NGES R4.0: A Major Leap in Pharmaceutical Industry's Digital Transformation
With the rapid popularization of AI technology, the global pharmaceutical industry is entering a crucial stage of digital transformation. Today, Tencent Healthcare has launched Next Generation Engagement Suite R4.0 (NGES R4.0) to help global pharmaceutical multinationals leverage cutting-edge AI technology for their operations and expansion into the Chinese market.NGES 4.0 leverages AI technology to enhance efficiency, refine management, and ensure compliance across various pharmaceutical scenarios such as multi-channel marketing, meeting management, and Customer Relationship Management (CRM). By deeply integrating large AI models, NGES R4.0 is set to revolutionize the pharmaceutical industry.
Image: https://www.globalnewslines.com/uploads/2025/04/a8bc2743295d11330ed7eb651f6f1e82.jpg
Amid the sweeping digital wave today, AI technology is penetrating various industries at an unprecedented speed, and the pharmaceutical field is no exception. Tencent Healthcare has keenly captured this development trend and actively promoted the intelligent development of the industry with the help of large models and AI tools. The upgrade of the NGES R4.0 version integrates AI technology deeply into the entire process of pharmaceutical digital marketing, enabling pharmaceutical companies to achieve more precise customer touchpoints and more efficient resource management.
One of the standout features of this upgrade is the seamless switching between Tencent Hunyuan and DeepSeek models. The dual-model capability, combined with fine-tuning of the pharmaceutical industry knowledge base, empowers NGES R4.0 to assist companies in efficiently producing professional academic content.. It not only supports core scenarios such as academic abstract generation, intelligent title optimization, and professional content expansion but also ensures the professionalism and compliance of medical expressions through a dual-track mechanism, by integrating an industry-standard medical terminology library and manual review, while enhancing content production efficiency. In addition, this version can automatically adapt to the stylistic features of different academic scenarios, achieving full-process intelligent processing from initial draft generation to compliance verification, significantly reducing labor intervention costs.
NGES R4.0 also presets more than 10 types of professional labels, such as diseases, drugs, and patient types, through the medical master data tag system, enabling out-of-the-box intelligent annotation capabilities. Meanwhile, by innovatively integrating the rule engine of the medical knowledge base and the semantic understanding technology of large models, it can automatically parse the core elements of medical literature, patient education materials, and other content. Moreover, it supports manual secondary calibration to optimize label accuracy, increasing the annotation accuracy rate by 60% compared to traditional models. The human-machine collaborative workflow design further improves annotation efficiency while ensuring the rigor of professional terms.
From a broader perspective, Tencent Healthcare not only provides the pharmaceutical industry with a powerful intelligent tool like NGES R4.0 but also launches AI solutions from the cloud to the local end, comprehensively supporting multiple scenarios such as clinical trials, drug research and development, and medical translation. The introduction of distributed cloud and AI knowledge engines provides strong support for enterprises to quickly deploy and optimize AI applications.
As AI technology continues to be deeply applied in the pharmaceutical industry, there is a need for enterprises to keep pace. The release of Tencent Healthcare's NGES R4.0 will help global multinationals use technology to drive their business practices in the Chinese market, driving the industry towards a more intelligent and efficient future.
Media Contact
Company Name: Tencent Healthcare
Contact Person: Tabris Zhen
Email: Send Email [http://www.universalpressrelease.com/?pr=tencent-healthcare-unveils-nges-r40-a-major-leap-in-pharmaceutical-industrys-digital-transformation]
Country: China
Website: https://healthcare.tencent.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Tencent Healthcare Unveils NGES R4.0: A Major Leap in Pharmaceutical Industry's Digital Transformation here
News-ID: 3995328 • Views: …
More Releases from Getnews
LS Team Launches Post-Typhoon Relief Fund to Support Reconstruction Efforts in t …
Philippines - November 18, 2025 - Following two consecutive and devastating typhoons on November 4 and November 10, the Philippines experienced severe storms, widespread flooding, and extensive damage to homes and infrastructure. In response to this crisis, LS Team swiftly mobilized emergency aid and demonstrated strong corporate social responsibility by launching a dedicated relief and reconstruction initiative to support affected communities.
Immediate Disaster Response and Emergency Aid
Image: https://storage.googleapis.com/mmstudio-images/gallery/w3vsmsTFm0OJ9cBTyypPagPbEzX2/89176099-1763373469-1.jpg
Within hours of the…
Bear and BSPK Partner to Transform Retail Commerce Through Unified Digital and I …
Image: https://www.globalnewslines.com/uploads/2025/11/1763505725.jpg
Strategic Alliance Combines Shopify Expertise with AI-Powered Clienteling Platform
Bear, a leading Shopify-focused digital agency [https://www.beargroup.com] with 18 years of technical expertise, announces a strategic partnership with BSPK, an advanced unified commerce AI platform [https://www.bspk.com/] serving premium and luxury brands. This collaboration creates a powerful synergy between Bear's eCommerce development capabilities and BSPK's sophisticated clienteling technology [https://www.bspk.com/clienteling101], enabling brands to deliver personalized customer experiences across all retail touchpoints.
Partnership Addresses Critical…
Pittsburgh's #1 Home Improvement Company Warns: Gutters Shouldn't Be "Stuffed" T …
Powerhouse Home Improvements warns homeowners that with Pittsburgh's early freeze, clogged gutters can quickly lead to leaks, ice dams, and costly damage. To help prevent holiday headaches, they're offering free safety checks, winter readiness reports, and priority service-reminding everyone that stuffing belongs on your plate, not in your gutters.
Image: https://authoritypresswire.com/wp-content/uploads/2025/11/Untitled-design.png
With Thanksgiving around the corner and National Stuffing Day falling on November 21, Powerhouse Home Improvements-recently named #1 in Pittsburgh-is using…
Oscar Health Contracting 2026 in Alabama and Mississippi Made Simple through FMO …
Hollywood, FL - Oscar Health, Inc. ("Oscar") is expanding its ACA health insurance plans and contracting for agents and brokers for the upcoming 2026 Open Enrollment Period, bringing affordable, tech-driven healthcare options to more individuals and families across Alabama and Mississippi.
This expansion marks a milestone for Oscar as the company continues its mission to make quality healthcare more accessible. The Oscar experience will now reach 573 counties across 20 states…
More Releases for NGES
Peripheral Artery Disease Market is growing globally with the rapid pace and For …
Market Research Future has just added another market concentrate to its broad research portfolio, titled “Global Peripheral Artery Disease Market Research Report Forecast to 2023". The report offers shrewd bits of knowledge and utilizations careful examination of market components to measure advertise size and advancement.
Market Scenario:
Peripheral artery disease are also known as peripheral vascular diseases or peripheral Occlusive diseases. Peripheral artery diseases cause narrowing of artery due to deposition of…
Peripheral Artery Disease Market Is Anticipated to Rise at a CAGR of 6.5% with J …
The Peripheral Artery Disease Market is growing mainly due to rising prevalence of arterial diseases. According to a recent study report published by the Market Research Future, the peripheral artery disease market is booming and expected to gain prominence over the forecast period. The market is forecast to demonstrate a spectacular growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated…
Peripheral Artery Disease Market is Growing Massively with Johnson & Johnson, Me …
Global Peripheral Artery Disease Market - Segmentation
Global Peripheral artery disease Market is segmented into types of devices which includes Stents, angioplasty balloon catheters, Drug-Eluting Balloons, Atherectomy devices and other. Stents is further sub segmented into balloon-expandable and self-expandable. Atherectomy devices are further sub segmented into rotational, orbital, laser and directional.
Get Sample Report @ https://www.marketresearchfuture.com/sample_request/1540
By drugs they are segmented as Lipid-lowering drugs, blood pressure lowering drug, glucose regulating drug, clot preventing…
Peripheral Artery Disease Market 2018 by Johnson & Johnson, Medtronic, Sanofi S. …
Global Peripheral Artery Disease Market - Key Players
Johnson & Johnson (U.S), Medtronic (Ireland), Sanofi S.A. (France), Abbott Laboratories (U.S), AstraZeneca Plc. (UK), Boston Scientific Corporation (U.S), Angioscore, Inc. (U.S), Bristol-Myers Squibb Company (US), Betagenon AB (Sweden), Proteon Therapeutics, Inc. (US), Merck & Co., Inc. (US), Bayer HealthCare Pharmaceuticals (Germany), Symic Bio, Inc. (US), CardioVascular BioTherapeutics, Inc. (US), nGes MG, Inc. (Japan), TheraVasc Inc. (US) and many more.
Get Sample Report @…
Peripheral Artery Disease Market 2018 - Major Participants: Johnson & Johnson, M …
The Peripheral Artery Disease Market is growing mainly due to rising prevalence of arterial diseases. According to a recent study report published by the Market Research Future, the peripheral artery disease market is booming and expected to gain prominence over the forecast period. The market is forecast to demonstrate a spectacular growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated…
Peripheral Artery Disease Market to Expand Exponentially Registering Phenomenal …
Global Peripheral Artery Disease Market - Regional Analysis
On regional basis, Global Peripheral artery market is segmented as North America, Europe, Asia Pacific and Middle East and Africa. Due to a huge people suffering from major or minor peripheral disease problem helps to increase the market of North America. North America has the largest market for peripheral artery disease. Due to increasing obese and diabetic patients the demand for the drugs…
